Loading clinical trials...
Loading clinical trials...
A Phase 1, Observer-Blind, Randomized, Active Controlled Trial to Evaluate the Safety and Immunogenicity of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age
Conditions
Interventions
Pn-MAPS30plus
PCV20
Locations
2
Australia
GSK Investigational Site
Norwood, South Australia, Australia
GSK Investigational Site
Camberwell, Victoria, Australia
Start Date
March 10, 2026
Primary Completion Date
December 24, 2026
Completion Date
December 24, 2026
Last Updated
April 16, 2026
NCT06238297
NCT07406334
NCT05976581
NCT03100760
NCT06602557
NCT06113432
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions